A new fixed-dose combination medication for adults with chronic hepatitis C virus (HCV) genotype 1 or 4 infections has gained FDA approval. Of the estimated 3 million people with HCV infection in the United States, genotype 1 is the most common and genotype 4 is among the least common (http://1.usa.gov/1ZXciW4).
Elbasvir and grazoprevir, marketed as Zepatier, is taken orally once daily with or without ribavirin. The drug’s safety and efficacy with or without ribavirin were evaluated in 6 clinical studies that included 1373 patients who had chronic HCV genotype 1 or 4 infections with or without cirrhosis. The studies were designed to determine whether patients still had detectable virus levels in their blood 12 weeks after completing treatment.
Voelker R. Combination Treatment for HCV. JAMA. 2016;315(11):1101. doi:10.1001/jama.2016.2070